TOP TEN perturbations for 39833_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39833_at
Selected probe(set): 214246_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39833_at (214246_x_at) across 6674 perturbations tested by GENEVESTIGATOR:

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):-2.3844862
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

tumor supernatant activation study 3 / untreated memory CD4 T-cell sample

Relative Expression (log2-ratio):-2.3614607
Number of Samples:4 / 3
Experimental tumor supernatant activation study 3
Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:---
Control untreated memory CD4 T-cell sample
Memory (CD45RA-) CD4+ T-cells were isolated from peripheral blood of healthy female donors and incubated in X-VIVO 20 medium for 24 hours, before harvest for RNA isolation.

Alzheimer's disease study 7 / normal pyramidal neuron (hippocampus)

Relative Expression (log2-ratio):2.3187428
Number of Samples:10 / 12
Experimental Alzheimer's disease study 7
Pyramidal neurons collected from the CA1 region of the hippocampus of clinically and neuropathologically classified late-onset Alzheimer´s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent.
Control normal pyramidal neuron (hippocampus)
Pyramidal neurons collected from the CA1 region of the hippocampus of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density.

T-helper activation study 1 (160min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):-2.071888
Number of Samples:2 / 2
Experimental T-helper activation study 1 (160min)
Alloantigen specific helper T-cells were stimulated for 160min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):2.0159807
Number of Samples:2 / 3
Experimental glioma study 17 (small cell glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

T-helper activation study 1 (240min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):-1.9573975
Number of Samples:2 / 2
Experimental T-helper activation study 1 (240min)
Alloantigen specific helper T-cells were stimulated for 240min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

Langerhans cell histiocytosis study 2 (multisystem) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):-1.9296789
Number of Samples:2 / 10
Experimental Langerhans cell histiocytosis study 2 (multisystem)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland).
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

T-helper activation study 1 (140min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):-1.8978481
Number of Samples:2 / 2
Experimental T-helper activation study 1 (140min)
Alloantigen specific helper T-cells were stimulated for 140min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic) / expO skin cancer study 1 (malignant melanoma, NOS; metastatic)

Relative Expression (log2-ratio):1.8918009
Number of Samples:2 / 9
Experimental expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary squamous cell carcinoma (NOS) of the skin.
Control expO skin cancer study 1 (malignant melanoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary malignant melanoma (NOS) of the skin.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):1.8794394
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---